U.S. markets open in 7 hours 36 minutes
  • S&P Futures

    4,221.00
    +11.00 (+0.26%)
     
  • Dow Futures

    33,345.00
    +85.00 (+0.26%)
     
  • Nasdaq Futures

    13,441.75
    +49.75 (+0.37%)
     
  • Russell 2000 Futures

    1,975.00
    +5.50 (+0.28%)
     
  • Crude Oil

    91.79
    -0.14 (-0.15%)
     
  • Gold

    1,801.40
    -12.30 (-0.68%)
     
  • Silver

    20.47
    -0.28 (-1.34%)
     
  • EUR/USD

    1.0285
    -0.0017 (-0.16%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2195
    -0.0023 (-0.19%)
     
  • USD/JPY

    133.1570
    +0.2840 (+0.21%)
     
  • BTC-USD

    24,622.60
    +1,704.10 (+7.44%)
     
  • CMC Crypto 200

    580.05
    +48.82 (+9.19%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Investors in OncoCyte (NASDAQ:OCX) have made a strong return of 202% over the past year

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

OncoCyte Corporation (NASDAQ:OCX) shareholders have seen the share price descend 23% over the month. Despite this, the stock is a strong performer over the last year, no doubt about that. During that period, the share price soared a full 202%. So we think most shareholders won't be too upset about the recent fall. Only time will tell if there is still too much optimism currently reflected in the share price.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

Check out our latest analysis for OncoCyte

OncoCyte isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last year OncoCyte saw its revenue grow by 2,566%. That's well above most other pre-profit companies. And the share price has responded, gaining 202% as we previously mentioned. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. The strong share price rise indicates optimism, so there may be a better opportunity for buyers as the hype fades a bit.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

This free interactive report on OncoCyte's balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

We're pleased to report that OncoCyte shareholders have received a total shareholder return of 202% over one year. That's better than the annualised return of 0.6% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 4 warning signs we've spotted with OncoCyte .

We will like OncoCyte better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.